IDSA News - November 2014
(Print All Articles)
Now Available: Updated Guideline for Kidney Disease in HIV Patients
An updated HIVMA and IDSA guideline for the treatment of chronic kidney disease in patients infected with HIV is available online. Published in the Nov. 1 issue of Clinical Infectious Diseases, the new document updates guidance last issued in 2005. Antiretroviral therapy (ART) is beneficial for the 5 to 10 percent of HIV-infected patients with reduced kidney function, with the exception of tenofovir—the most widely prescribed ART—which can lead to moderate kidney damage in some patients, according to the updated guideline.
“Research shows HIV patients who have clinically decreased kidney function are less likely to be prescribed ART, probably because physicians and other health care providers are concerned that many of these medications are cleared by the kidneys and don’t want to cause further harm,” said Gregory Lucas, MD, associate professor at Johns Hopkins School of Medicine and co-chair of the guideline panel. “But the outlook for HIV patients with kidney disease is much better now that we have numerous effective treatments for HIV, many of which are not cleared by the kidneys.”
The guideline also recommends kidney transplantation as a viable option in HIV-infected patients whose kidneys are failing. Despite previous concerns that these patients would not fare well on the immunosuppressive therapy necessary to prevent the body from rejecting the organ, initial research suggests they are as likely to survive and maintain a functioning organ as transplant recipients without HIV infection.
Those caring for HIV patients should monitor both kidney function, by estimating glomerular filtration rate (GFR), and kidney damage, with urinalysis or urine protein, the guideline recommends. As many as one in 10 people with HIV have decreased kidney function, and up to twice as many may have other evidence of kidney damage.
Mobile device and pocket-card versions of the updated guideline are available for use at the point of care. These and other clinical tools can be accessed through the practice guidelines section of the IDSA website.
FDA Approves First Combination Pill for HCV
In early October, the Food and Drug Administration (FDA) approved a combination ledipasvir-sofosbuvir pill (Harvoni) to treat chronic hepatitis C virus infection. The pill is the first combination pill approved to treat chronic HCV genotype 1 infection and the first approved regimen that does not require administration with interferon or ribavirin.
IDSA offers two email services to help members stay informed of new drug approvals and similar updates from FDA and the Centers for Disease Control and Prevention (CDC). Content includes a range of topics, including drug warnings, recalls, and outbreak investigations. Recent alerts have included:
IDSA members can sign up for these services online. (To subscribe, check the appropriate boxes to receive CDC’s Health Alert Network [HAN] messages and/or alerts from FDA, and provide your email address and name where indicated.)
Is Your Facility Experiencing Antibiotic Shortages?IDSA members are urged to report drug shortages directly to FDA and to copy IDSA staff at email@example.com.
EIN Update: Tracking the Enterovirus D68 Outbreak
The Emerging Infections Network (EIN) is a forum for infectious diseases consultants and public health officials to report information on clinical phenomena and epidemiological issues with public health significance. Any diagnostic or therapeutic recommendations and all opinions presented are those of the individual contributor. They do not necessarily represent the views of EIN, IDSA (EIN’s sponsor), or the Centers for Disease Control and Prevention (CDC), which funds EIN. The reader assumes all risks in using this information.EIN members recently highlighted the network’s utility as an early warning system when several contributors noted an unusual increase in severe respiratory infections in children in August.
“We are seeing a lot of children with severe respiratory illness that for some has resulted in ICU admissions,” likely due to a rhinovirus/enterovirus, a member in Missouri wrote in an initial post. “In some children this has exacerbated their asthma, and in others it has appeared to cause an asthma-like illness with many requiring continuous albuterol.”
While some respondents noted no unusual activity in their communities at the time, members in Georgia, Illinois, Indiana, and Iowa, responded with similar reports of increased cases:
“We are also seeing this same phenomenon in our ICU,” the Illinois respondent wrote. “Many children with no (or very remote) history of wheezing at all are ending up intubated—one child is on extracorporeal membrane oxygenation (ECMO)—with severe asthma-like respiratory failure.”
A subsequent article published in the Sept. 12 Morbidity and Mortality Weekly Report (MMWR) described two clusters of enterovirus D68 (EV-D68) infections in Kansas City, Mo., and Chicago, and noted that investigations into other suspected clusters were ongoing. As of Oct. 27, the Centers for Disease Control and Prevention (CDC) reported that it or state public health laboratories had confirmed 1,035 people in 47 states and the District of Columbia with respiratory illness caused by EV-D68. (Additional EV-D68 resources for health professionals on clinical evaluation, reporting, treatment, laboratory testing, diagnostic methods, and infection control recommendations are available on the CDC website.)
In early October, following several reported cases of muscle weakness or paralysis in children following respiratory illnesses with EV-D68, an EIN member on the West Coast shared a perspective on the possibility of similar cases in adults.
“In California, we have been following what we think are very similar cases for approximately two years,” the member wrote. “While the majority of our cases are in the pediatric population, we are also seeing cases in the adult age group (approximately 25 percent of our cases are in adult patients). Adult ID clinicians should consider this in the differential if they are consulted about a patient with unexplained neurologic illness especially if there are spinal cord lesions.”
The California member cited two Oct. 10 MMWR articles as important sources of information for providers:
“If you do see an adult patient with a similar syndrome,” the member noted, “it’s important to test cerebrospinal fluid for enterovirus, but even more important to test for enterovirus in respiratory tract specimens. We have been requesting both nasopharyngeal and throat specimens.”
Email the Emerging Infections Network
The Emerging Infections Network (EIN) is a provider-based sentinel network designed to help the public health community detect trends in emerging infectious diseases.
A joint project of IDSA and the Pediatric Infectious Diseases Society (PIDS) with funding from the Centers for Disease Control and Prevention (CDC), EIN tracks emerging infectious diseases and keeps the public health community up to date with new disease trends, difficult cases, and other issues affecting members’ clinical practices. The Network provides a great opportunity for members to share knowledge quickly across large geographical distances. Both IDSA and PIDS members are eligible to join. Click here for more information or to join EIN.
HIV Provider Resources: Outpatient Billing and Coding; ACOs and HIV Care
HIVMA has developed a series of resources to support clinicians with implementation of the Affordable Care Act (ACA). These tools, which are supported by grant funding from the MAC AIDS Fund and Janssen Pharmaceuticals, will be housed in a new section of HIVMA’s website, www.hivclinician.org, coming soon.
Billing and Coding for Outpatient HIV Services (PDF)
This guide to coding (available as a pocket guide and wall poster) is designed to help clinicians locate proper codes and key elements for HIV outpatient care billing. They include reference lookups for patient history, physical exams, risk levels, and criteria for medical decision making. An upcoming HIVMA webinar will provide an overview of the resources by coding experts and will include time for participants to ask questions.
Accountable Care Organizations (ACOs) and HIV Care: Considerations for HIV Medical Providers
This issue brief, released in September, covers ACO basics and outlines key considerations for HIV medical providers. An accompanying webinar featured HIVMA Board Member Stephen Boswell, MD, president and CEO of Fenway Health, who shared his experience as a Ryan White provider participating in an ACO. The webinar recording and slide set are available online together with the issue brief.
IDSA Testifies Before Congress on Antimicrobial Resistance
Then-IDSA President Barbara Murray testified before Congress in September on the need for a coordinated federal strategy to combat antibiotic resistance and spur research and development for new antibiotics. The hearing was convened as part of the House Energy and Commerce Committee's 21st Century Cures Initiative aimed at accelerating the discovery, development, and delivery of promising new treatments to patients. While on Capitol Hill, Dr. Murray also met with key congressional leaders to urge them to advance legislation to address resistance and incentivize the development of new antibiotics.Dr. Murray thanked Congress for its leadership in enacting the Generating Antibiotic Incentives Now (GAIN) Act in 2012 and urged lawmakers’ support of the Antibiotic Development to Advance Patient Treatment (ADAPT) Act, which would remove regulatory barriers to antibiotic development by allowing companies to receive Food and Drug Administration (FDA) approval for certain antibiotics with the use of smaller clinical trials. You can take three minutes to echo Dr. Murray’s message by emailing your congressional representative and urging him or her to cosponsor the ADAPT Act using IDSA’s convenient online advocacy center.
She also discussed the benefits of other Congressional proposals that would assist with antibiotic research and development, including tax credits for drug companies that develop new antibiotics, reforming reimbursement models for antibiotics, providing more effective support through federal agencies, and establishing a public private partnership for antibiotic R&D.
In her testimony, Dr. Murray also expressed IDSA’s support of a coordinated government response to antibiotic resistance including well-coordinated federal leadership; sustained and meaningful involvement of non-government stakeholders; antibiotic stewardship programs; enhanced surveillance and data collection on antibiotic use and resistance patterns; and research on novel strategies, best practices and evaluation of methods to prevent, control, and eradicate antimicrobial resistant organisms. Finally, Dr. Murray recommended increased investment in diagnostics research, regulatory approval pathways for needed diagnostics, strengthening diagnostics reimbursement and support for outcomes research to demonstrate the impact of diagnostics on patient care.
Inaugural Meeting of IDSA’s S-FARAs reported in the September issue of IDSA News, IDSA has launched a new stakeholder group, U.S. Stakeholder Forum on Antimicrobial Resistance (S-FAR), to bring together a diverse set of groups to work collaboratively and inform federal policy. Thus far, over 90 national organizations have joined, representing medical and allied health professionals, hospitals and other healthcare facilities, patients and consumers, public health entities, research and advocacy groups, industry representatives, and international health organizations. The group held its inaugural meeting during IDWeek last month in Philadelphia. Dr. Murray reiterated S-FAR’s call for the U.S. to take a leadership role in addressing the complex, multi-faceted public health crisis of antimicrobial resistance with multi-pronged solutions involving all stakeholders.
At the meeting, key White House staff provided an overview of President Obama’s Executive Order and National Strategy for Combating Antibiotic-Resistance and the President’s Council on Science and Technology (PCAST) Report. Participants also engaged in moderated discussions led by IDSA experts on specific topics related to antimicrobial resistance including surveillance, stewardship, research, product development and data collection and antimicrobial use in veterinary medicine and agriculture. Federal agency representatives also provided updates on federal activities in each of these areas. The group will continue to collaborate on opportunities to advocate for the initiatives discussed during the meeting.
IDSA Urges Boost in Funding for Public Health Agencies in FY 2016 Budget
Ahead of the president’s budget request for the 2016 fiscal year (FY), IDSA urged the Obama administration to push for stronger funding for public health agencies. The Centers for Disease Control and Prevention, the National Institutes of Health, and other agencies have seen dramatic funding reductions in recent years, and increases in overall funding levels will be necessary to maintain and promote excellence in patient care, prevention, public health, education, and research in ID, the Society explained in a September letter (PDF) to the White House’s Office of Management and Budget. The president’s budget request, which is generally released in February, serves as the beginning of the annual appropriations process on Capitol Hill.
IDSA and HIVMA also encouraged members to contact Congress this fall and urge their representatives to complete the appropriations process for FY 2015 to prevent new funding cuts from taking effect. Congress will return from recess this month to continue work on the FY 2015 spending bills. One of two conclusions to the FY 2015 appropriations process is likely: Congress may pass a yearlong continuing resolution that flat funds the government through October, or Congress may package the spending bills together into a single measure that sets priorities among agencies and programs. IDSA calls on Congress to take the latter path, so that ID programs can be provided necessary funding increases.
Learn more about IDSA’s advocacy efforts and how you can help by visiting the new online advocacy center. Consider joining the IDSA/HIVMA Membership Advocacy Program (MAP) (log in required). MAP members support the Society’s advocacy work by contacting members of Congress or talking to the media about ID priorities.
Society Calls for More Funding of ID Comparative Effectiveness Research
IDSA recently urged the Patient-Centered Outcomes Research Institute (PCORI) to consider more ID research projects when reviewing applications for funding.
Since PCORI’s formation in 2010 under the Affordable Care Act, comparative effectiveness research focusing on acute infections has remained noticeably underrepresented among the projects PCORI has supported, IDSA noted in a September letter (PDF) to the organization. Multi-drug resistant microbes, health care-associated infections, and emerging infectious diseases continue to be major challenges to patient care, and require strong, patient-engaged research to assess the effectiveness of new advances in clinical care, such as rapid diagnostics or alternative prevention and treatment, the Society’s letter said. PCORI staff responded enthusiastically to IDSA’s letter and are interested in further engagement with the Society. IDSA will continue to look for opportunities to encourage PCORI to fund more ID research.
Members of IDSA who have received PCORI grant funding and are willing to share their experiences, tips, or pointers, for the benefit of other IDSA members who may wish to pursue PCORI grants are encouraged to contact Greg Frank, IDSA’s program officer for science and research policy, at firstname.lastname@example.org.
On the Frontlines of the HIV/TB Response in Africa: Impacts and Gaps
In October, staff from the IDSA Center for Global Health Policy travelled to Tanzania, one of the countries hit hardest by HIV and tuberculosis, to host congressional staffers on visits to treatment and prevention programs. They spoke to people providing and receiving services to address the impact of these diseases, met with civil society representatives, and discussed the impacts of, and gaps in, current efforts.
Visit Science Speaks, the center’s blog, for updates from the trip and stay tuned for more in-depth stories to come. Dispatches from Africa included:
Live from Cape Town and Barcelona: Biomedical HIV Prevention and the Fight Against TB
the blog of the IDSA Center for Global Health Policy, was on the scene
with on-site coverage of the world’s first global scientific conference
devoted to biomedical HIV prevention, HIV Research for Prevention 2014
(HIV R4P), Oct. 28-31, in Cape Town, South Africa, and the 45th Union
World Conference on Lung Health, Oct. 28-Nov. 1, in Barcelona, Spain.
Check out the blog for updates
from Cape Town on treatment as prevention, pre-exposure prophylaxis,
microbicides, vaccine research, and more, from conference presentations
and discussions, with input from leading investigators who attended the
meeting. Posts included:
From Barcelona, Science Speaks reported
on new research findings on tuberculosis (TB) and the increasing
interplay between TB and other health conditions, the world’s current
response to TB and future goals, and related developments in the global
fight against TB:
Members on the Move
Stuart Feinstein, MD, has joined Health Quest Medical Practice in Poughkeepsie, N.Y., and will head its new Division of Infectious Diseases. In practice since 1985, Dr. Feinstein earned his medical degree from SUNY Downstate Medical Center in Brooklyn, and completed post-graduate work at Montefiore Medical Center and a fellowship in infectious disease at Albert Einstein College of Medicine, both in the Bronx.
Rana A. Hajjeh, MD, FIDSA, director of the Division of Bacterial Diseases at the Centers for Disease Control and Prevention, has been named the 2014 Federal Employee of the Year. The award recognizes Dr. Hajjeh’s efforts to lead a global campaign to convince some of the world’s poorest countries to use the Haemophilus influenzae type b (Hib) vaccine to fight bacterial meningitis and pneumonia, an initiative that is estimated will save the lives of 7 million children by 2020. One of several honors presented annually by the nonprofit, nonpartisan Partnership for Public Service to celebrate excellence in the federal civil service, the award recognizes a federal employee whose professional contributions exemplify the highest attributes of public service.
For her globally recognized work to reduce infections within health care environments, Elaine L. Larson, RN, PhD, FIDSA, has been chosen to receive the 2014 John Stearns Medal for Distinguished Contributions in Clinical Practice from the New York Academy of Medicine. Associate dean for research at Columbia University School of Nursing, Dr. Larson will receive the award at an academy event in November.
Are you a member on the move? Do you know someone who is? Contact Jennifer Morales at email@example.com so we can announce it to our membership.
Abuelo, Carolina, MD
Al-Sweih, Noura, MD
Bhambri, Vishal, MD
Blackburn, Julie, MD
Boccumini, Louis, MS
Brugger, Caroline, BSN, FNP, MSN, NP, RN
Coyle, Larissa, PharmD
El Khoury, Joseph, MD
Fajardo, Rhoda Lynn, MD
Farrell, Alanna, PharmD
Ghesquiere, Wayne, MD
Gilchrist, Kim, MD
Guevara Pulido, Fredy, MD
Gugkaeva, Zina, PharmD
Hoffman-Terry, Margaret, MD
Hughes, Nancy, MPH, NP
Kalra, Lalit, MD
Karimi, Kamran, MD
Koirala, Bibek, MD
Logan, James, MD
Mokaddas, Eiman, MD
Morales, Ayana, MD
Mukherjee, Dip Narayan, MD
Narvaez Penaloza, Cesar Ramon
Patel, Trisha, PharmD
Patil, Sudershana, MD
Pingol, Maria Christina, FNP, MSN, RN
Ranade, Prachi, MD
Ritz, Daniel, PhD
Ruiz Alvarez, Felix, MD
Schmidt, Desiree, PA-C
Shihabuddin, Courtney, MSN
Solante, Marietta, MD
Soria Segarra, Carmen, MD
Tan, Daniel, MD
Uribe Rodriguez, Luis, MD
van der Hilst, Jeroen, MD, PhD
Villavicencio, Carmenchu Marie
Willis, English, MD
Wulf, Mireille, MD
Akova, Murat, MD
Altamirano, Jessica, MD
Balling, David, MD
Graziani, Amy, PharmD, RPh
Harbertson, Judith, PhD
Hogan, Karen, MS
Kareliya, Hiten, MD
Kitchell, Ellen, MD
Patel, Vipul Madhubhai, MD
Plummer, Francis, MD
Sudhakar, Shiv, MD
Takhar, Sukhjit, MD, MS
Thompson, Tamara, MD
Bhat, Haimavathi, DO
Chahin, Abdullah, MD
Chaudhari, Shilpa, MD
De Luca, Maia, MD
Dunn, Dallas, MD
Elsaghir, Hend, MD
Graves, Susannah, MD
Harris, John, MD
Hebert, Jennifer, MD
Hernandez Munoz, Francisco, MD
Hypolite, Tiara, MD
Isogai, Mihoko, MD
Khan, Hassan, MBBS, MD
Kogilwaimath, Siddharth, MD
Labalo, Vladimir, MD
Law, Nancy, DO
Liu, Bo, PhD
McManus, Kathleen, MD, MS
Moon, Juhi, MD
Nambiar, Puja, MD
Ocampo Alves, Giovanna, MD
Platt, Mihae, MD, PhD
Rayan, Sonya, MD
Reeves, Jeffrey, MD
Rosenthal, Elana, MD
Shapiro, Julie Ann, DO
Shein, Thwe, MD
Siddiqui, Farhan, MD
Torres-Velazco, Jeniffer, MD
Urcis, Rafael, MD
Viswanathan, Anusha, MD
Winters, John, MD
Wong, Jim, MD
Bello, Kathryn, DO
Chehab, Hiba, MD
DeRose, Joseph, DO
Funakoshi, Yu, MD
George, Griffen Taylor, MD
Gordy, Anna Lina-Karin, MD
Harboe, Zitta, MD, PhD
Jones, Sara, PharmD
Lata, Christopher, MD, MSc
Miglis, Cristina, PharmD
Natarajan, Padma, MD
Sandling, Marcus, MD
Uda, Kazuhiro, MD
Young, Adam, DO
Koontz, Rachel, MPH, BSN, RN
Lemieux, Jacob, PhD
Swanenberg, Irene, MD
HIV Minority Clinical Fellowship Program: December 12 Application Deadline
Since 2007 the HIV Medicine Association’s (HIVMA) Minority Clinical Fellowship program has supported 17 African-American and Latino physicians in pursuing careers in HIV medicine. The program awards up to two one-year fellowships, providing a pathway for HIV clinical training for African American and Latino physicians committed to working with medically underserved patient populations. During the training year, fellows manage the ongoing care of patients with HIV disease under the supervision of an HIVMA mentor.
The award includes a $60,000 stipend plus funding for benefits for one year and support for additional learning opportunities. Applications are being accepted for the 2015 to 2016 fellowship year, which starts July 1, 2015. Eligible candidates will be African American or Latino physicians who are within the first five years of starting their medical practice and have a demonstrated interest in HIV medicine. The fellowship is not intended for physicians who plan to complete an infectious diseases training program.
The application along with information on current and past fellows is available online. The deadline to apply for next year is December 12, 2014. Contact Nathan Danskey at firstname.lastname@example.org with questions or for more information.
Help Support This Program
Member donations and industry support to IDSA’s Education and Research Foundation make this valuable program possible. Please consider making a donation today to help jump start a career. For more information about other programs supported by the Foundation please visit the new webpage www.idsafoundation.org.
From the President
As each day brings new challenges and developments in the fight to keep the Ebola outbreak under control, the need for the leadership and expertise of the ID professional is clear. An international, coordinated response is essential in bringing this humanitarian crisis to an end and IDSA is contributing to that response in many ways.
As I begin my term as president of IDSA in the midst of the Ebola outbreak, one thing is certain: the need for the expertise and leadership of infectious diseases professionals and of this Society continues to be great.
Each day brings new developments and challenging circumstances, be they worsening of the epidemic in West Africa, new cases of infection cared for here in the U.S., new government protocols, reactions by local government officials, or managing potential public hysteria. I continue to be impressed by the commitment of the membership of this organization to respond to the crisis with the best scientific information, training and guidance. As many have said, a coordinated international response is needed to get this outbreak under control, and IDSA is contributing to that response in many ways.
From the time the outbreak began in West Africa, ID experts have been assisting the Centers for Disease Control and Prevention (CDC) and other government agencies in their response by lending expertise. Most recently, IDSA reached out to the newly appointed Ebola czar, Ron Klain, to let him know that we are available and ready to actively participate in the U.S. and international response to this public health threat.
IDSA’s Rapid Communications Task Force, led by Marguerite A. Neill, MD, FIDSA, has kept the membership abreast of the latest information, including CDC alerts, lessons learned at Emory University, and guidance from IDSA.
In response to actions taken by several states to impose mandatory involuntary quarantines on healthcare workers returning from Ebola-affected countries, IDSA issued a statement opposing such policies. The statement strongly iterated the scientific facts about transmission, highlighted the systems that are in place to prevent transmission, and expressed concern about the unintended consequence of such a policy on the willingness of healthcare workers to lend their assistance where it is so desperately needed in West Africa. Controlling the outbreak at its source in West Africa is the most important way to control the spread of this disease.
To that end, the IDSA Board of Directors has approved $100,000 to fund 40 service grants that are being made available through our Center for Global Health Policy to members who volunteer in West Africa. The details of these grants are still in development, and information will be online in the coming days.
Another significant challenge we face is controlling public fear. It is critical that we as ID professionals continue to communicate the scientific facts, emphasizing that while Ebola is certainly a serious disease, it is not transmitted through casual contact, and that the likelihood of a generalized outbreak in the United States is low. In just the last month, IDSA spokespersons have fielded nearly 100 media requests, helping to educate the public about transmission, hospital and healthcare worker preparedness, and the U.S. response to the cases that have surfaced domestically.
We are facing the largest outbreak of Ebola in history. The knowledge and experience of the infectious diseases professional is critical to bringing it to an end. I personally thank each of you for the contributions you have and will continue to make, whether that is by helping to educate your colleagues, prepare your facility, or simply to quell the fears of those not in our field by continuing to emphasize the best science available.
The State of the Society: Reports from IDWeek 2014 Business Meeting
In addition to tripling the membership of medical students and residents, Dr. Murray reported in her State of the Society address that the Society is financially sound and stands in good stead to pursue its strategic goals including promoting domestic and global public health, research, and the value of the ID specialist; attracting medical students to the field; and combatting antimicrobial resistance.
Before passing the gavel of the IDSA presidency to Steven Calderwood, MD, FIDSA, Barbara Murray, MD, FIDSA, reported on the “State of the Society” during the recent IDWeek 2014. Emphasizing the vital role that members play, Dr. Murray touched on the many initiatives and programs in which the Society has been engaged over the past year including significant work in the fight against antimicrobial resistance, continued efforts to communicate the value of the ID specialist, strides in improving care for patients with HCV, and advancements toward our goal of developing new diagnostic tests.
As noted in the Secretary’s report, last year the Society added a new membership category for medical students and residents in order to foster interest in the field of infectious diseases. The total membership in these categories combined has tripled in number over the past year. IDSA now represents more than 10,000 physicians and scientists who specialize in ID, including more than 1,300 members outside the United States.
The Treasurer’s report indicates that the Society is financially sound. The Board of Directors is confident in the Society’s ability to continue to address strategic priorities over the next few years, including the Society’s efforts to promote domestic and global public health, research, and the value of the ID specialist; to attract medical students to the field; and to combat antimicrobial resistance.
Full reports from the President, Secretary and Treasurer can be found in the Board of Directors section of the IDSA website.
Board of Directors Election Results
The following members were elected to serve on the IDSA Board of Directors:
William G. Powderly, MD, FIDSA
Board MembersThe following members were elected to serve on the HIVMA Board of Directors:
Janet A. Englund, MD, FIDSA
Thomas Fekete, MD, FIDSA
Lawrence P. Martinelli, MD, FIDSA
Wendy Armstrong, MD, FIDSA
Carlos del Rio, MD, FIDSA
Joel Ang, MD, FIDSA
Judith Feinberg, MD, FIDSA
Lisa K. Fitzpatrick, MD, MPH, FIDSA
Rajesh T. Gandhi, MD, FIDSA
Carole A. Hohl, MHS, PA-C
IDWeek 2014: Post Meeting Resources
IDWeek attendees can claim continuing medical education (CME) or continuing pharmacy education (CPE) credit, print a receipt, obtain a certificate of attendance, and download full session abstract PDFs by visiting the IDWeek website. You can also catch up on the sessions you missed—or review sessions you want to see again—by using your free access to the digital library.
If you attended IDWeek in Philadelphia, you can claim continuing medical education (CME) or continuing pharmacy education (CPE) credit, print a receipt, obtain a certificate of attendance, and download full session abstract PDFs at www.idweek.org/post-meeting-tools. While you’re there, catch up on the sessions you missed—or review sessions you want to see again—by using your free access to the digital library.
The IDWeek presentation by Bruce Ribner, MD, MPH, FIDSA, on lessons learned caring for Ebola patients in the U.S. is available to all to view online. To assist ID specialists in their ongoing preparedness efforts, a clinical summary of the presentation is also available.
Abstracts presented in Philadelphia have also been permanently archived as part of Open Forum Infectious Diseases, IDSA’s new open access journal.
You can share your feedback on IDWeek in return for an opportunity to enter to win a free registration for IDWeek 2015, Oct. 7-11, in San Diego. Take the online survey today! It should take only about five minutes to complete.
Congratulations to the 2014 Society Award Winners!
Each year, IDSA and the IDSA Education and Research Foundation honor individuals who have made outstanding achievements in the field of infectious diseases. This year’s Alexander Fleming Award, the Society’s greatest honor, went to Martin J. Blaser, MD, FIDSA. Read about other honorees.
IDSA and the IDSA Education and Research Foundation offer awards to individuals to honor outstanding achievements in the field of infectious diseases. Learn about the 2014 winners below. It's never too early to begin thinking about nominations for next year. The deadline for nominations is April 1, 2015.
Alexander Fleming Award
The Alexander Fleming Award is granted in recognition of a career that reflects major contributions to the acquisition and dissemination of knowledge about infectious diseases.
Martin J. Blaser, MD, FIDSA, is a world renowned researcher and clinician who has greatly advanced the medical field’s knowledge of Helicobacter pylori and its role in human health and disease. His groundbreaking scientific work on the organism helped untangle its complex molecular behavior, illuminating its ability to not only harm, but also possibly benefit, human health. The conceptual framework he developed for how H. pylori interacts with humans—a dynamic equilibrium that allows bacterial persistence at low cost to the host—has become a general model for understanding the persistence of other co-adapted microbes. His work has led to exciting new research—by Dr. Blaser, a wide group of collaborators, and other investigators—on H. pylori and other indigenous microbiota, exploring the dynamic relationships between the human microbiome and health. A scientist of unusual breadth and a past president of IDSA, Dr. Blaser has conducted research over more than 30 years spanning topics including Legionnaires’ disease, Campylobacter infections, Guillain-Barré syndrome, salmonellosis, plague, and anthrax, among others.
Oswald Avery Award
The Oswald Avery Award recognizes outstanding achievements in an area of infectious diseases by an individual member or fellow of IDSA who is 45 or younger.
Sara E. Cosgrove, MD, MS, FIDSA, FSHEA, an international leader in antimicrobial stewardship, has helped advance the stewardship field and improve patient care. Dr. Cosgrove’s early work with collaborators investigating Staphylococcus aureus infections led to widely cited articles that have helped set the standard of care and increased the urgency for prevention of these infections. Her publication demonstrating the nephrotoxicity of low-dose gentamicin for the treatment of S. aureus bacteremia received the Emanuel Wolinsky Award for the most outstanding study in Clinical Infectious Diseases in 2009. Her contributions have moved the field of antimicrobial stewardship forward in a unique way by examining not only the impact of stewardship but also how these programs can be implemented to achieve lasting, evidence-based prescribing. Dr. Cosgrove’s 2012 study of the impact of antimicrobial stewardship across five academic medical centers was the first multi-center study of its kind and is a model for other researchers.
Rochelle P. Walensky, MD, MPH, FIDSA, has had a significant impact on national and global policies for HIV screening and treatment. Her research has changed HIV policy, ultimately extending resources to individuals most in need. Her 2005 study of widespread HIV testing demonstrated that routine screening in the general U.S. population was both cost-effective and clinically justified. Her 2006 paper in The Journal of Infectious Diseases was the first to clearly demonstrate the extraordinary survival benefit of combination antiretroviral therapy (ART), and was critical to expanding treatment resources in the U.S. In South Africa, her analysis showing a clear benefit from starting ART earlier than previously recommended led, in part, to a change in international HIV treatment guidelines in resource-limited settings. The comprehensive modeling tool that Dr. Walensky and her colleagues have developed is now used to study the impact and costs of HIV interventions globally. Her research has also underscored the importance of maintaining and expanding U.S. investments in HIV research and care.
The Walter E. Stamm Mentor Award
Named to honor the memory of Walter E. Stamm, MD, FIDSA, a past president of IDSA, this award was created to recognize individuals who have served as exemplary mentors and is presented to an IDSA member or fellow who has been exceptional in guiding professional growth of infectious diseases professionals.
G. Ralph Corey, MD, FIDSA, has guided the professional growth of countless ID physicians. At Duke University, he created innovative training programs in clinical epidemiology and global health, providing transformational experiences that have influenced many career paths. Now in his fourth decade of training physicians, he continues to teach and mentor housestaff, in addition to his ongoing work in research, clinical care, and global health. One of the traits that characterizes Dr. Corey is his tendency to take a back seat in order to give his junior colleagues recognition. He has more than 230 peer-reviewed publications, and in more than 150 of them, one of his mentees was a first or last author. In his role at the International Collaboration on Endocarditis, Dr. Corey has ensured that all of the participating investigators—especially younger ones—are recognized for their work. His mentees cite Dr. Corey as one of the most valuable and inspiring mentors in their careers. Many continue to rely on his guidance and good humor, and consider him a role model for their own mentoring activities.
The Society Citation is a discretionary award given in recognition of exemplary contribution to IDSA, an outstanding discovery in the field of infectious diseases, or a lifetime of outstanding achievement in a given area—either in research, clinical investigation, or clinical practice.
David L. Thomas, MD, MPH, FIDSA, was honored for his effective leadership and substantial contributions to the rapidly evolving field of viral hepatitis. He has played a key role in IDSA’s ongoing effort with the American Association for the Study of Liver Diseases (AASLD) and the International Antiviral Society-USA (IAS-USA) to develop new guidance for the treatment of hepatitis C virus (HCV) infection. This guidance is being updated in real time at HCVguidelines.org to keep pace with improved diagnostic tools and new drug options. In addition, under his leadership, IDSA’s Hepatitis Task Force has developed a broad range of educational activities, including webinars, a Maintenance of Certification module, an online core curriculum, and sessions for IDWeek. The Task Force also helped advocate for the U.S. Preventive Services Task Force to strengthen its recommendation that all Americans born between 1945 and 1965 be screened for hepatitis C. Dr. Thomas’s energy, focus, and determination have been critical to the success of IDSA’s efforts on hepatitis.
Clinical Teacher Award
The Clinical Teacher Award honors a career involved in teaching clinical infectious diseases to fellows, residents, or medical students and recognizes excellence as a clinician and motivation to teach the next generation.
Nesli Basgoz, MD, FIDSA, has inspired countless trainees—and her fellow faculty—with her expertise, clinical acumen, and unmatched commitment to her patients. Her gift for teaching has been recognized with multiple teaching awards. Colleagues and former patients praise Dr. Basgoz’s unmatched bedside manner and willingness to go above and beyond to meet the needs of patients. At Massachusetts General Hospital, she has worked with colleagues to develop a continuity of care initiative, guidelines on “How to Be a Subspecialty Fellow,” an outpatient parenteral antibiotic therapy (OPAT) program, and a comprehensive, multidisciplinary HIV program. Throughout her career, Dr. Basgoz has been a consummate clinician and educator whose immense dedication, talent, and commitment to excellence have inspired all who have known her.
Watanakunakorn Clinician AwardEliot W. Godofsky, MD, is a leading expert in the management and treatment of patients with HCV infection. He is well known for his strong commitment to patients and his efforts to advance clinical care through research. In the 1990s, recognizing there were no viral hepatitis experts in western Florida to whom he and others in his community could send their patients, Dr. Godofsky became the local expert and provided an invaluable service to countless patients. He pioneered hepatitis care a decade before interest in integrating this care into ID practice became more common. Today, he is an active member of IDSA’s Hepatitis Task Force and a contributor to the joint IDSA-AASLD project that issues timely new clinical guidance on the treatment of HCV to help clinicians keep pace with newly approved, direct-acting antiviral medications. He has participated as a principal investigator in nearly 100 Food and Drug Administration-sponsored clinical trials focusing on HIV and HCV, which have helped provide better and safer treatments for patients.
Named to honor the memory of Dr. Chatrchai Watanakunakorn, this award is given annually by the IDSA Education and Research Foundation to an IDSA member or fellow in recognition of outstanding achievement in the clinical practice of infectious diseases.
The 2014 awards were presented during IDWeek in Philadelphia. More information about the Society Awards, including how to submit nominations for 2015, is available on the IDSA website.